Ketamine and phencyclidine: the good, the bad and the unexpected

被引:133
|
作者
Lodge, D. [1 ]
Mercier, M. S. [1 ]
机构
[1] Univ Bristol, Sch Physiol & Pharmacol, Ctr Synapt Plast, Bristol BS1 3NY, Avon, England
基金
英国惠康基金;
关键词
METHYL-D-ASPARTATE; DISCRIMINATIVE STIMULUS PROPERTIES; NMDA RECEPTOR HYPOFUNCTION; RAT SPINAL NEURONS; PARVALBUMIN-IMMUNOREACTIVE NEURONS; NICOTINIC ACETYLCHOLINE-RECEPTORS; MISMATCH NEGATIVITY GENERATION; SCHIZOPHRENIA DRUG DISCOVERY; CEREBRAL GLUCOSE-UTILIZATION; GLUTAMATE ANTAGONIST MK-801;
D O I
10.1111/bph.13222
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The history of ketamine and phencyclidine from their development as potential clinical anaesthetics through drugs of abuse and animal models of schizophrenia to potential rapidly acting antidepressants is reviewed. The discovery in 1983 of the NMDA receptor antagonist property of ketamine and phencyclidine was a key step to understanding their pharmacology, including their psychotomimetic effects in man. This review describes the historical context and the course of that discovery and its expansion into other hallucinatory drugs. The relevance of these findings to modern hypotheses of schizophrenia and the implications for drug discovery are reviewed. The findings of the rapidly acting antidepressant effects of ketamine in man are discussed in relation to other glutamatergic mechanisms.
引用
收藏
页码:4254 / 4276
页数:23
相关论文
共 50 条